董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shmuel Cabilly | 男 | Independent Director | 76 | 未披露 | 1229.33 | 2026-04-27 |
| Roni Mamluk | 女 | Independent Director | 59 | 未披露 | 未持股 | 2026-04-27 |
| Rick D. Scruggs | 男 | Chief Commercial Officer and Director | 66 | 42.69万美元 | 2320.00 | 2026-04-27 |
| Dror Ben Asher | 男 | Chairman of the Board and Chief Executive Officer and Director | 60 | 62.18万美元 | 3256.06 | 2026-04-27 |
| Kenneth Reed | 男 | Independent Director | 72 | 未披露 | 769.00 | 2026-04-27 |
| Ofer Tsimchi | 男 | Independent Director | 66 | 未披露 | 1060.00 | 2026-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Razi Ingber | 男 | Chief Financial Officer | 42 | 38.03万美元 | 2899.00 | 2026-04-27 |
| Rick D. Scruggs | 男 | Chief Commercial Officer and Director | 66 | 42.69万美元 | 2320.00 | 2026-04-27 |
| Dror Ben Asher | 男 | Chairman of the Board and Chief Executive Officer and Director | 60 | 62.18万美元 | 3256.06 | 2026-04-27 |
| Gilead Raday | 男 | Chief Operating Officer | 51 | 32.10万美元 | 2699.00 | 2026-04-27 |
| Adi Frish | 男 | Chief Corporate and Business Development Officer | 56 | 35.60万美元 | 2892.11 | 2026-04-27 |
| Guy Goldberg | 男 | Chief Business Officer | 50 | 41.18万美元 | 2387.00 | 2026-04-27 |
董事简历
中英对照 | 中文 | 英文- Shmuel Cabilly
-
Shmuel Cabilly，他曾担任我们的董事会成员（2010年8月26日以来），并任职我们薪酬委员会（2011年5月5日以来）。他是免疫学领域的科学家和发明家。任职the Backman Research Institute（位于希望之城）时，他发起一个重组抗体生产的新突破性技术的开发，并获得专利，也被称为“Cabilly Patent”。他也曾担任Ethrog Biotechnology的联席创始人兼首席科学官，在那里他曾发明了干缓冲技术生产液体凝胶电泳的免费一次性装置，以及冷凝分子分离区域至小胶区域。该技术于2001年出售给Invitrogen公司。他是投资者，也担任一些公司的董事会成员，其中包括BioKine Therapeutics Ltd.、Neuroderm Ltd.、Biologic Design Ltd.、Ornim Inc、Efranat Ltd.他持有the Ben Gurion University of Beer Sheva（位于以色列）的生物学理学硕士学位、the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学工商管理硕士学位，以及the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学博士学位。
Shmuel Cabilly has served as a member of Redhill Biopharma Ltd.'s board of directors since August 2010. Dr. Cabilly is a scientist and inventor in the field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the "Cabilly Patent." Dr. Cabilly was also a co founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly serves as a board member at several companies, including BioKine Therapeutics Ltd., Minovia Ltd., Alonbio Ltd. and Raziel Therapeutics Ltd. Dr. Cabilly holds a B.Sc. in Biology from the Ben Gurion University of Beer Sheva, Israel, an M.Sc. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel, and a Ph.D. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel. - Shmuel Cabilly，他曾担任我们的董事会成员（2010年8月26日以来），并任职我们薪酬委员会（2011年5月5日以来）。他是免疫学领域的科学家和发明家。任职the Backman Research Institute（位于希望之城）时，他发起一个重组抗体生产的新突破性技术的开发，并获得专利，也被称为“Cabilly Patent”。他也曾担任Ethrog Biotechnology的联席创始人兼首席科学官，在那里他曾发明了干缓冲技术生产液体凝胶电泳的免费一次性装置，以及冷凝分子分离区域至小胶区域。该技术于2001年出售给Invitrogen公司。他是投资者，也担任一些公司的董事会成员，其中包括BioKine Therapeutics Ltd.、Neuroderm Ltd.、Biologic Design Ltd.、Ornim Inc、Efranat Ltd.他持有the Ben Gurion University of Beer Sheva（位于以色列）的生物学理学硕士学位、the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学工商管理硕士学位，以及the Hebrew University of Jerusalem（位于以色列）的免疫学和微生物学博士学位。
- Shmuel Cabilly has served as a member of Redhill Biopharma Ltd.'s board of directors since August 2010. Dr. Cabilly is a scientist and inventor in the field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the "Cabilly Patent." Dr. Cabilly was also a co founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly serves as a board member at several companies, including BioKine Therapeutics Ltd., Minovia Ltd., Alonbio Ltd. and Raziel Therapeutics Ltd. Dr. Cabilly holds a B.Sc. in Biology from the Ben Gurion University of Beer Sheva, Israel, an M.Sc. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel, and a Ph.D. in Immunology and Microbiology from the Hebrew University of Jerusalem, Israel.
- Roni Mamluk
-
Roni Mamluk自2015年3月起担任公司的首席发展官。她于2013年4月-2015年3月担任公司的首席执行官，并担任不同的职位，承担着日益重要的责任，包括运营总监和研发副总裁（2006-2013年4月）。她也担任董事会成员（2013年4月-2015年3月）。自加入公司，Mamluk博士担任发展的领导职位，是公司专有的瞬态渗透增强剂（Transient Permeability Enhancer， TPE，技术平台）的主要发明者之一。她也领导着公司TPE平台的口服生长抑素的发展及持续改进。Mamluk博士从Adnexus Therapeutics股份有限公司（Adnexus Therapeutics,Inc）跳槽加入我们公司，建立并领导非临床研发。Mamluk博士拥有希伯来大学（Hebrew University）学士学位和博士学位。她也参加哈佛医学院儿童医院在血管生成领域的博士后课程。
Roni Mamluk joined Board of Directors in June 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma Israel Ltd. since April 2017. Dr. Mamluk served as Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013 including Chief Operating Officer and Vice President, Research and Development. She also served as a member of Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children's Hospital/Harvard Medical School in the field of angiogenesis. - Roni Mamluk自2015年3月起担任公司的首席发展官。她于2013年4月-2015年3月担任公司的首席执行官，并担任不同的职位，承担着日益重要的责任，包括运营总监和研发副总裁（2006-2013年4月）。她也担任董事会成员（2013年4月-2015年3月）。自加入公司，Mamluk博士担任发展的领导职位，是公司专有的瞬态渗透增强剂（Transient Permeability Enhancer， TPE，技术平台）的主要发明者之一。她也领导着公司TPE平台的口服生长抑素的发展及持续改进。Mamluk博士从Adnexus Therapeutics股份有限公司（Adnexus Therapeutics,Inc）跳槽加入我们公司，建立并领导非临床研发。Mamluk博士拥有希伯来大学（Hebrew University）学士学位和博士学位。她也参加哈佛医学院儿童医院在血管生成领域的博士后课程。
- Roni Mamluk joined Board of Directors in June 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma Israel Ltd. since April 2017. Dr. Mamluk served as Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013 including Chief Operating Officer and Vice President, Research and Development. She also served as a member of Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children's Hospital/Harvard Medical School in the field of angiogenesis.
- Rick D. Scruggs
-
Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
Rick D. Scruggs has served as Redhill Biopharma Ltd.'s Chief Commercial Officer since February 2020 and served as Redhill Biopharma Ltd.'s Chief Operations Officer, U.S. Operations since January 1, 2019, and as a member of Redhill Biopharma Ltd.'s board of directors since January 1, 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant (now Bausch Health) in March 2015. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix's commercial organization, serving in various sales and commercial trade related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix's innovative products and intellectual property. Mr. Scruggs also served as the head of the board of directors of Oceana Therapeutics, Salix's European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina. - Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
- Rick D. Scruggs has served as Redhill Biopharma Ltd.'s Chief Commercial Officer since February 2020 and served as Redhill Biopharma Ltd.'s Chief Operations Officer, U.S. Operations since January 1, 2019, and as a member of Redhill Biopharma Ltd.'s board of directors since January 1, 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant (now Bausch Health) in March 2015. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix's commercial organization, serving in various sales and commercial trade related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix's innovative products and intellectual property. Mr. Scruggs also served as the head of the board of directors of Oceana Therapeutics, Salix's European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.
- Dror Ben Asher
-
Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
Dror Ben Asher has served as Redhill Biopharma Ltd.'s Chief Executive Officer and as a director since August 2009. Since May 2011, Mr. Ben Asher has also served as Chairman of Redhill Biopharma Ltd.'s board of directors. From January 2002 to November 2010, Mr. Ben Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben Asher holds an LLB from the University of Leicester, U.K., an MJur from Oxford University, U.K. and completed LLM studies at Harvard University. - Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
- Dror Ben Asher has served as Redhill Biopharma Ltd.'s Chief Executive Officer and as a director since August 2009. Since May 2011, Mr. Ben Asher has also served as Chairman of Redhill Biopharma Ltd.'s board of directors. From January 2002 to November 2010, Mr. Ben Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben Asher holds an LLB from the University of Leicester, U.K., an MJur from Oxford University, U.K. and completed LLM studies at Harvard University.
- Kenneth Reed
-
Kenneth Reed， 2009年12月15日起，他担任我公司董事会成员。他是皮肤科医生，在Kenneth Reed MD PC的名下进行个人实践。他目前担任Minerva Biotechnologies Corporation的董事会成员。他在布朗大学（Brown University）获得学士学位，在新泽西医科与牙科大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
Kenneth Reed has served as a member of Redhill Biopharma Ltd.'s board of directors since December 2009 and serves as a member of Redhill Biopharma Ltd.'s audit committee and compensation committee. Dr. Reed is a board certified dermatologist and Mohs surgeon. Dr. Reed received his B.A. from Brown University in the U.S. and an M.D from the University of Medicine and Dentistry of New Jersey in the U.S. Dr. Reed is a board certified dermatologist with over 25 years of clinical experience since completing the Harvard Medical School Residency Program in Dermatology. Dr. Reed is also a co founder of Early Cell, a prenatal diagnostics company, Prescient Pharma and Lispiro. - Kenneth Reed， 2009年12月15日起，他担任我公司董事会成员。他是皮肤科医生，在Kenneth Reed MD PC的名下进行个人实践。他目前担任Minerva Biotechnologies Corporation的董事会成员。他在布朗大学（Brown University）获得学士学位，在新泽西医科与牙科大学（University of Medicine and Dentistry of New Jersey）获得医学博士学位。
- Kenneth Reed has served as a member of Redhill Biopharma Ltd.'s board of directors since December 2009 and serves as a member of Redhill Biopharma Ltd.'s audit committee and compensation committee. Dr. Reed is a board certified dermatologist and Mohs surgeon. Dr. Reed received his B.A. from Brown University in the U.S. and an M.D from the University of Medicine and Dentistry of New Jersey in the U.S. Dr. Reed is a board certified dermatologist with over 25 years of clinical experience since completing the Harvard Medical School Residency Program in Dermatology. Dr. Reed is also a co founder of Early Cell, a prenatal diagnostics company, Prescient Pharma and Lispiro.
- Ofer Tsimchi
-
Ofer Tsimchi， 2011年5月4日起，他担任我公司董事外部董事，2011年5月5日起，担任审计委员会成员和薪酬委员会主席；2008年起，担任Polysack Plastic Industries Ltd.和Polysack-Agriculture Products的董事会主席， 2006年起，担任控股公司Danbar Group Ltd.的合伙人。他目前担任Polysack Plastic Industries Ltd, Kidron Industrial Materials Ltd., Amutat Zionut 2000 Danbar Group Ltd，和Polysack Agriculture Hi-Technologies的董事会成员。他在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得经济学和农业学士学位。
Ofer Tsimchi has served as a director on Redhill Biopharma Ltd.'s board of directors, as Chairman of Redhill Biopharma Ltd.'s compensation committee and as a member of Redhill Biopharma Ltd.'s audit committee since May 2011. Since June 2024, Mr. Tsimchi has also served as Chairman of Redhill Biopharma Ltd.'s audit committee. From 2008 to 2012, Mr. Tsimchi served as the Chairman of the board of directors of Polysack Plastic Industries Ltd. and Polysack Agriculture Products, served as a board member of Caesarstone Ltd. and Danbar Group Ltd and since 2006, he has served as a Partner in the Danbar Group Ltd., a holding company. Mr. Tsimchi currently serves on the board of directors of Maabarot Products Ltd, Allmed Solutions Ltd. and Novolog Ltd. Mr. Tsimchi received his BA in Economics and Agriculture from the Hebrew University of Jerusalem, Israel. The board of directors has determined that Mr. Tsimchi is a financial and accounting expert under Israeli law. - Ofer Tsimchi， 2011年5月4日起，他担任我公司董事外部董事，2011年5月5日起，担任审计委员会成员和薪酬委员会主席；2008年起，担任Polysack Plastic Industries Ltd.和Polysack-Agriculture Products的董事会主席， 2006年起，担任控股公司Danbar Group Ltd.的合伙人。他目前担任Polysack Plastic Industries Ltd, Kidron Industrial Materials Ltd., Amutat Zionut 2000 Danbar Group Ltd，和Polysack Agriculture Hi-Technologies的董事会成员。他在以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得经济学和农业学士学位。
- Ofer Tsimchi has served as a director on Redhill Biopharma Ltd.'s board of directors, as Chairman of Redhill Biopharma Ltd.'s compensation committee and as a member of Redhill Biopharma Ltd.'s audit committee since May 2011. Since June 2024, Mr. Tsimchi has also served as Chairman of Redhill Biopharma Ltd.'s audit committee. From 2008 to 2012, Mr. Tsimchi served as the Chairman of the board of directors of Polysack Plastic Industries Ltd. and Polysack Agriculture Products, served as a board member of Caesarstone Ltd. and Danbar Group Ltd and since 2006, he has served as a Partner in the Danbar Group Ltd., a holding company. Mr. Tsimchi currently serves on the board of directors of Maabarot Products Ltd, Allmed Solutions Ltd. and Novolog Ltd. Mr. Tsimchi received his BA in Economics and Agriculture from the Hebrew University of Jerusalem, Israel. The board of directors has determined that Mr. Tsimchi is a financial and accounting expert under Israeli law.
高管简历
中英对照 | 中文 | 英文- Razi Ingber
Razi Ingber自2023年5月1日起担任Redhill Biopharma Ltd.的首席财务官，在其被任命为公司首席财务官之前的2018年2月至2023年5月期间，曾在公司担任多个财务职务。Ingber先生拥有丰富的财务经验，擅长财务报告和会计、财务规划、交易和业务分析。在2011年至2018年期间，Ingber先生曾在普华永道以色列公司担任多个职位，最终担任审计经理，负责领导多家公共和私营公司的审计团队。Ingber先生拥有特拉维夫大学的硕士学位和学士学位，是一名注册会计师。
Razi Ingber has served as Redhill Biopharma Ltd.'s Chief Financial Officer since May 1, 2023, and between February 2018 and May 2023, prior to his appointment as Chief Financial Officer of the Company, served in various financial positions at the Company. Mr. Ingber has extensive financial experience, specializing in financial reporting and accounting, financial planning, transactions and business analytics. Between 2011 and 2018, Mr. Ingber held several positions at PwC Israel, ultimately serving as an audit manager responsible for leading audit teams of several public and private companies. Mr. Ingber holds an M.A. and a B.A. from Tel Aviv University and is a Certified Public Accountant.- Razi Ingber自2023年5月1日起担任Redhill Biopharma Ltd.的首席财务官，在其被任命为公司首席财务官之前的2018年2月至2023年5月期间，曾在公司担任多个财务职务。Ingber先生拥有丰富的财务经验，擅长财务报告和会计、财务规划、交易和业务分析。在2011年至2018年期间，Ingber先生曾在普华永道以色列公司担任多个职位，最终担任审计经理，负责领导多家公共和私营公司的审计团队。Ingber先生拥有特拉维夫大学的硕士学位和学士学位，是一名注册会计师。
- Razi Ingber has served as Redhill Biopharma Ltd.'s Chief Financial Officer since May 1, 2023, and between February 2018 and May 2023, prior to his appointment as Chief Financial Officer of the Company, served in various financial positions at the Company. Mr. Ingber has extensive financial experience, specializing in financial reporting and accounting, financial planning, transactions and business analytics. Between 2011 and 2018, Mr. Ingber held several positions at PwC Israel, ultimately serving as an audit manager responsible for leading audit teams of several public and private companies. Mr. Ingber holds an M.A. and a B.A. from Tel Aviv University and is a Certified Public Accountant.
- Rick D. Scruggs
Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
Rick D. Scruggs has served as Redhill Biopharma Ltd.'s Chief Commercial Officer since February 2020 and served as Redhill Biopharma Ltd.'s Chief Operations Officer, U.S. Operations since January 1, 2019, and as a member of Redhill Biopharma Ltd.'s board of directors since January 1, 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant (now Bausch Health) in March 2015. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix's commercial organization, serving in various sales and commercial trade related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix's innovative products and intellectual property. Mr. Scruggs also served as the head of the board of directors of Oceana Therapeutics, Salix's European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.- Rick D. Scruggs，他曾一直担任业务发展执行副总裁（2011年1月以来）。他此前曾担任高级副总裁，负责业务拓展（从2009年1月到2011年1月）。他此前也曾担任副总裁，负责业务拓展（从2006年1月到2009年1月）。从2004年1月到2006年1月，他曾担任副总裁，负责商业发展。从2000年到2006年，他曾担任Salix公司的多种销售和商业贸易相关职务。加入Salix公司之前，他曾担任Watson公司的管理市场董事（从1997年5月到2000年7月）。此前，他曾担任Oclassen公司的董事，负责管理市场和贸易（从1995年1月到1997年2月）。加入Oclassen公司之前，他曾担任Johnson & Johnson公司和Ciba-Geigy公司的多种销售和营销职务，并不断被提拔。他持有Appalachian State University的刑事司法的学士学位。
- Rick D. Scruggs has served as Redhill Biopharma Ltd.'s Chief Commercial Officer since February 2020 and served as Redhill Biopharma Ltd.'s Chief Operations Officer, U.S. Operations since January 1, 2019, and as a member of Redhill Biopharma Ltd.'s board of directors since January 1, 2016. Mr. Scruggs most recently served as Executive Vice President of Business Development at Salix until its acquisition by Valeant (now Bausch Health) in March 2015. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix's commercial organization, serving in various sales and commercial trade related positions. Mr. Scruggs was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix's innovative products and intellectual property. Mr. Scruggs also served as the head of the board of directors of Oceana Therapeutics, Salix's European subsidiary. Mr. Scruggs holds a B.S. in Criminal Justice from the Appalachian State University in North Carolina.
- Dror Ben Asher
Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
Dror Ben Asher has served as Redhill Biopharma Ltd.'s Chief Executive Officer and as a director since August 2009. Since May 2011, Mr. Ben Asher has also served as Chairman of Redhill Biopharma Ltd.'s board of directors. From January 2002 to November 2010, Mr. Ben Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben Asher holds an LLB from the University of Leicester, U.K., an MJur from Oxford University, U.K. and completed LLM studies at Harvard University.- Dror Ben Asher，2009年8月3日起，他担任我公司首席执行官和董事；2011年5月4日起，担任我公司董事会主席；2002年1月至2010年11月，担任P.C.M.I. Ltd.的经理，该公司是ProSeed Capital Holdings CVA的附属机构，为我公司提供咨询服务。他目前担任Agrea Ltd.的董事。他在英国莱斯特大学（University of Leicester）获得法学学士学位，在英国牛津大学（Oxford University）获得法学硕士学位，并在美国哈佛大学（Harvard University）完成了法学硕士学习。
- Dror Ben Asher has served as Redhill Biopharma Ltd.'s Chief Executive Officer and as a director since August 2009. Since May 2011, Mr. Ben Asher has also served as Chairman of Redhill Biopharma Ltd.'s board of directors. From January 2002 to November 2010, Mr. Ben Asher served as a manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA. Mr. Ben Asher holds an LLB from the University of Leicester, U.K., an MJur from Oxford University, U.K. and completed LLM studies at Harvard University.
- Gilead Raday
Gilead Raday，2012年12月5日起，他担任我公司与产品发展高级副总裁 ；2010年11月至2012年12月，担任的公司与产品发展副总裁；2010年1月至2010年10月，担任肿瘤药物开发公司Sepal Pharma Plc.的临时首席执行官，2009年1月至2009年12月，担任独立顾问，负责生命科学领域的商业发展和项目管理；2004至2008年，担任投资银行Charles Street Securities Europe, LLP的合伙人，负责生命科学领域。他目前是Sepal Pharma Plc.和 ViDAC Limited的董事会成员。他曾担任Morria Biopharmaceuticals Plc.,Vaccine Research International Plc., TKsignal Plc.和Miras Medical Imaging Plc.的董事会成员。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得神经生物学硕士学位，在英国剑桥大学（Cambridge University）获得生物技术管理硕士学位。
Gilead Raday has served as Redhill Biopharma Ltd.'s Chief Operating Officer since April 2016. From December 2012 until March 2016, Mr. Raday served as Senior Vice President Corporate and Product Development. From November 2010 to December 2012, Mr. Raday served as Redhill Biopharma Ltd.'s Vice President Corporate and Product Development. From January 2010 until October 2010, Mr. Raday served as Interim Chief Executive Officer of Sepal Pharma Plc., an oncology drug development company, and from January 2009 to December 2009, he was an independent consultant, specializing in business development and project management in the field of life sciences. From 2004 to 2008, Mr. Raday was a partner in Charles Street Securities Europe, LLP, an investment banking firm, where he was responsible for the field of life sciences. Mr. Raday previously served on the boards of Sepal Pharma Plc., ViDAC Limited, Morria Biopharmaceuticals Plc., Vaccine Research International Plc., Tksignal Plc., and Miras Medical Imaging Plc. He received his M.Sc. in Neurobiology from the Hebrew University of Jerusalem, Israel, and an M.Phil. in Bioscience Enterprise from Cambridge University, U.K.- Gilead Raday，2012年12月5日起，他担任我公司与产品发展高级副总裁 ；2010年11月至2012年12月，担任的公司与产品发展副总裁；2010年1月至2010年10月，担任肿瘤药物开发公司Sepal Pharma Plc.的临时首席执行官，2009年1月至2009年12月，担任独立顾问，负责生命科学领域的商业发展和项目管理；2004至2008年，担任投资银行Charles Street Securities Europe, LLP的合伙人，负责生命科学领域。他目前是Sepal Pharma Plc.和 ViDAC Limited的董事会成员。他曾担任Morria Biopharmaceuticals Plc.,Vaccine Research International Plc., TKsignal Plc.和Miras Medical Imaging Plc.的董事会成员。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）获得神经生物学硕士学位，在英国剑桥大学（Cambridge University）获得生物技术管理硕士学位。
- Gilead Raday has served as Redhill Biopharma Ltd.'s Chief Operating Officer since April 2016. From December 2012 until March 2016, Mr. Raday served as Senior Vice President Corporate and Product Development. From November 2010 to December 2012, Mr. Raday served as Redhill Biopharma Ltd.'s Vice President Corporate and Product Development. From January 2010 until October 2010, Mr. Raday served as Interim Chief Executive Officer of Sepal Pharma Plc., an oncology drug development company, and from January 2009 to December 2009, he was an independent consultant, specializing in business development and project management in the field of life sciences. From 2004 to 2008, Mr. Raday was a partner in Charles Street Securities Europe, LLP, an investment banking firm, where he was responsible for the field of life sciences. Mr. Raday previously served on the boards of Sepal Pharma Plc., ViDAC Limited, Morria Biopharmaceuticals Plc., Vaccine Research International Plc., Tksignal Plc., and Miras Medical Imaging Plc. He received his M.Sc. in Neurobiology from the Hebrew University of Jerusalem, Israel, and an M.Phil. in Bioscience Enterprise from Cambridge University, U.K.
- Adi Frish
Adi Frish，2012年12月5日起，他担任我公司商业发展和发牌高级副总裁；2010年10月至2012年12月，担任商业发展和发牌副总裁；2006至2010年，担任内窥镜医疗设备公司，1998至2006年，担任律师事务所Y. Ben Dror & Co.的助理律师和合伙人。他在英国埃塞克斯大学（Essex University）获得法学学士学位，在以色列Bar-Ilan University 获得商业法学硕士学位。
Adi Frish has served as Redhill Biopharma Ltd.'s Chief Corporate and Business Development Officer since October 2020. From December 2012 to October 2020 Mr. Frish served as Redhill Biopharma Ltd.'s Senior Vice President Business Development and Licensing. From October 2010 to December 2012, Mr. Frish served as Redhill Biopharma Ltd.'s Vice President Business Development and Licensing. From 2006 to 2010, Mr. Frish served as the Chief Business Development at Medigus Ltd., a medical device company in the endoscopic field, and from 1998 to 2006, Mr. Frish was an associate and a partner at the law firm of Y. Ben Dror & Co. Mr. Frish holds an LLB from Essex University, U.K. and an LLM in Business Law from the Bar Ilan University, Israel.- Adi Frish，2012年12月5日起，他担任我公司商业发展和发牌高级副总裁；2010年10月至2012年12月，担任商业发展和发牌副总裁；2006至2010年，担任内窥镜医疗设备公司，1998至2006年，担任律师事务所Y. Ben Dror & Co.的助理律师和合伙人。他在英国埃塞克斯大学（Essex University）获得法学学士学位，在以色列Bar-Ilan University 获得商业法学硕士学位。
- Adi Frish has served as Redhill Biopharma Ltd.'s Chief Corporate and Business Development Officer since October 2020. From December 2012 to October 2020 Mr. Frish served as Redhill Biopharma Ltd.'s Senior Vice President Business Development and Licensing. From October 2010 to December 2012, Mr. Frish served as Redhill Biopharma Ltd.'s Vice President Business Development and Licensing. From 2006 to 2010, Mr. Frish served as the Chief Business Development at Medigus Ltd., a medical device company in the endoscopic field, and from 1998 to 2006, Mr. Frish was an associate and a partner at the law firm of Y. Ben Dror & Co. Mr. Frish holds an LLB from Essex University, U.K. and an LLM in Business Law from the Bar Ilan University, Israel.
- Guy Goldberg
Guy Goldberg，2012年7月16日起，他担任我公司首席商务官；2007年7月至2012年7月，担任Eagle Pharmaceuticals的副总裁，后担任商业运作高级副总裁， 该公司是位于新泽西的专业可注射药物开发公司；2004年至2007年，就职于医疗保健风险投资公司，2002至2004年，担任McKinsey & Company的顾问。他在耶鲁大学（Yale University）获得经济学和哲学学士学位，并在哈佛大学法学院（Harvard Law School）获得法学博士学位。
Guy Goldberg has served as Redhill Biopharma Ltd.'s Chief Business Officer since 2012. From 2007 to 2012, Mr. Goldberg served as Vice President and then as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. From 2004 to 2007, Mr. Goldberg was an associate at ProQuest Investments, a healthcare focused venture capital firm, and from 2002 to 2004, Mr. Goldberg was a consultant at McKinsey & Company. Mr. Goldberg holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.- Guy Goldberg，2012年7月16日起，他担任我公司首席商务官；2007年7月至2012年7月，担任Eagle Pharmaceuticals的副总裁，后担任商业运作高级副总裁， 该公司是位于新泽西的专业可注射药物开发公司；2004年至2007年，就职于医疗保健风险投资公司，2002至2004年，担任McKinsey & Company的顾问。他在耶鲁大学（Yale University）获得经济学和哲学学士学位，并在哈佛大学法学院（Harvard Law School）获得法学博士学位。
- Guy Goldberg has served as Redhill Biopharma Ltd.'s Chief Business Officer since 2012. From 2007 to 2012, Mr. Goldberg served as Vice President and then as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. From 2004 to 2007, Mr. Goldberg was an associate at ProQuest Investments, a healthcare focused venture capital firm, and from 2002 to 2004, Mr. Goldberg was a consultant at McKinsey & Company. Mr. Goldberg holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.